Press Releases
16 September 2019
LANDOVER, Md., Sept. 16, 2019 /PRNewswire/ -- Epilepsy Foundation today announced it is rolling out its Seizure Safe Schools initiative nationwide. It calls
Read more...16 September 2019
NEW YORK, Sept. 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment. The forum is being held at the Congress Center Basel in Basel, Switzerland on
Read more...LONDON and PHILADELPHIA, Sept. 16, 2019 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited or no treatment options, today announced that Joe Horrigan, MD, AMO Pharma's chief medical officer, prese
Read more...16 September 2019
PLYMOUTH MEETING, Pa., Sept. 16, 2019 /PRNewswire/ -- Harmony Biosciences, LLC (Harmony) announced today it will present clinical data on the efficacy and safety of WAKIX® (pitolisant) at the World Sleep 2019 meeting in Vancouver, Canada from September 20-25, 2019. In an oral presentation, results will be
Read more...16 September 2019
MELBOURNE, Australia, Sept. 16, 2019 /PRNewswire/ -- Benitec Biopharma (ASX: BLT, NASDAQ: BNTC), a gene therapy-focused biotechnology company developing novel genetic medicines derived from the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced their plans to complete three non-clinical studies that will facilitate the filing of an
Read more...16 September 2019
WHIPPANY, N.J., Sept. 16, 2019 /PRNewswire/ -- Bayer today announced Daniella Foster as the new Head of Public Affairs and Sustainability for the Consumer Health Division, effective September 16. In her new role, Daniella will be responsible for the development and execution of the Division's global Public Affairs and Sustainabil
Read more...16 September 2019
BOSTON, Sept. 16, 2019 /PRNewswire/ -- Oncoheroes Biosciences Inc. ("Oncoheroes") and Boehringer Ingelheim International GmbH ("Boehringer Ingelheim") have signed a worldwide, exclusive licensing agreement for volasertib, an investigational anti-cancer compound that was originally discovered and developed by Boehringer Ingelheim. Under the terms of this agreement Boehrin
Read more...16 September 2019
BOTHELL, Wash., Sept. 16, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction to
Read more...16 September 2019
SALT LAKE CITY, Sept. 16, 2019 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that a
Read more...16 September 2019
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ -- Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that it has executed an exclusive worldwide license agreement with Novartis under which Amplyx has acquired the rights to the Phase
Read more...
